GlobeNewswire by notified

CrossAmerica Partners LP Announces Issuance and Sale of Cumulative Preferred Membership Interests by its Subsidiary

Share

Allentown, PA, March 30, 2022 (GLOBE NEWSWIRE) -- To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

CrossAmerica Partners LP Announces Issuance and Sale of Cumulative Preferred Membership Interests by its Subsidiary

  • $25 million of preferred equity in CAPL JKM Holdings LLC issued to affiliates of Chairman Joseph V. Topper, Jr and Vice Chairman John B. Reilly, III
  • The net proceeds will be utilized to prepay a portion of the JKM Term Loan Credit Facility

Allentown, PA March 30, 2022 – CrossAmerica Partners LP (NYSE: CAPL) (“CrossAmerica” or the “Partnership”), a leading wholesale fuels distributor, convenience store operator and owner and lessor of real estate used in the retail distribution of motor fuels, today reported the issuance and sale of $25 million of Cumulative Preferred Membership Interests in its indirect, wholly owned subsidiary, CAPL JKM Holdings LLC. The preferred interests were issued and sold to entities affiliated with Joseph V. Topper, Jr., who indirectly controls and is the Chairman of the board of directors of CrossAmerica GP LLC, the general partner of the Partnership, and to John B. Reilly, III, the Vice Chairman of the board of directors of CrossAmerica GP LLC. The Cumulative Preferred Membership Interests are entitled to a 9.0% cumulative preferred return and are exchangeable, subject to certain terms and conditions, for common units of CrossAmerica, at an exchange price of $23.74 per common unit (or into cash, if the holder so elects). The net proceeds from the preferred interest issuance will be used to prepay a portion of the outstanding borrowings under the Term Loan Credit Facility of the Partnership's subsidiary, CAPL JKM Partners LLC.

“Our preferred equity issuance is an additional component in the financing of our $263 million acquisition of assets from 7-Eleven completed earlier this year. At acquisition, the purchase was funded entirely through borrowings under our credit facilities and today’s equity transaction will be used to reduce those borrowings,” said Charles Nifong, President and CEO of CrossAmerica. “The transaction also demonstrates the continued commitment to the Partnership of our Chairman, Joseph V. Topper Jr, and Vice Chairman, John B. Reilly, III, and our Board of Directors’ dedication to acting in the best interests of our common unitholders.”

The issuance and sale of the Cumulative Preferred Membership Interests were approved by the Board of Directors of CrossAmerica’s General Partner, following the approval by, and recommendation of, its independent Conflicts Committee. Skadden, Arps, Slate, Meagher & Flom LLP is acting as legal counsel to CrossAmerica.

CrossAmerica will be filing a Form 8-K with the Securities and Exchange Commission providing additional details of the preferred equity issuance.

About CrossAmerica Partners LP

CrossAmerica Partners LP is a leading wholesale distributor of motor fuels, convenience store operator and owner and lessee of real estate used in the retail distribution of motor fuels. Its general partner, CrossAmerica GP LLC, is indirectly owned and controlled by entities affiliated with Joseph V. Topper, Jr., the founder of CrossAmerica Partners and a member of the board of the general partner since 2012. Formed in 2012, CrossAmerica Partners LP is a distributor of branded and unbranded petroleum for motor vehicles in the United States and distributes fuel to approximately 1,750 locations and owns or leases approximately 1,150 sites. With a geographic footprint covering 34 states, the Partnership has well-established relationships with several major oil brands, including ExxonMobil, BP, Shell, Chevron, Sunoco, Valero, Gulf, Citgo, Marathon and Phillips 66. CrossAmerica Partners LP ranks as one of ExxonMobil’s largest distributors by fuel volume in the United States and in the top 10 for additional brands. For additional information, please visit www.crossamericapartners.com.

Contact

Randy Palmer (investors) at rpalmer@caplp.com

Cautionary Statement Regarding Forward-Looking Statements

Statements contained in this release that state the Partnership’s or management’s expectations or predictions of the future are forward-looking statements. The words “believe,” “expect,” “should,” “intends,” “estimates,” “target” and other similar expressions identify forward-looking statements. It is important to note that actual results could differ materially from those projected in such forward-looking statements. For more information concerning factors that could cause actual results to differ from those expressed or forecasted, see CrossAmerica’s Form 10-K or Forms 10-Q filed with the Securities and Exchange Commission, and available on the CrossAmerica’s website at www.crossamericapartners.com. The Partnership undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease16.5.2022 00:00:00 CEST | Press release

WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. “The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the tre

Cool Company Ltd. – Mandatory Notification of Trade15.5.2022 14:52:24 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Primary insider notification form

Monthly information related to total number of voting rights and shares composing the share capital – April 30, 202213.5.2022 18:00:00 CEST | Press release

Monthly information related to total number of voting rights and shares composing the share capital –April 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut(1) voting rights Total of net (2) voting rights December 31, 202131 018 55332 518 33932 515 839January 31, 202231 018 55332 518 33932 515 839February 28, 202231 018 55332 518 54732 516 047March 31, 202231 018 55332 518 54732 516 047April 30, 202231 018 55332 518 54732 516 047 (1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on t

Hövding ansöker om avnotering från Nasdaq First North Growth Market13.5.2022 17:45:00 CEST | Pressemelding

Styrelsen för Hövding Sverige AB (publ) (”Hövding”) har beslutat att ansöka om avnotering av Hövdings aktie från Nasdaq First North Growth Market (”First North”). Sista dag för handel på First North kommer att meddelas efter att Hövding erhållit bekräftelse om detta från Nasdaq. Fosielund Holding AB (”Fosielund”) offentliggjorde genom pressmeddelande den 13 januari 2022 ett offentligt budpliktserbjudande till aktieägarna i Hövding (”Erbjudandet”). Fosielund meddelande genom pressmeddelande den 16 februari 2022 att Fosielund (med närstående), efter redovisning av likvid i Erbjudandet, innehade 18 021 741 aktier motsvarande ca 65 procent av aktierna och rösterna. Den 8 april 2022 meddelade Fosielund genom pressmeddelande att de förvärvat en större post aktier i Hövding, varefter Fosielund innehade ca 88,7 procent av aktierna och rösterna samt en avsikt att förvärva ytterligare aktier. Den 4 maj 2022 meddelade Fosielund genom pressmeddelande att de förvärvat ytterligare aktier och att des

Fosielund Holding AB påkallar inlösen av återstående aktier i Hövding Sverige AB (publ)13.5.2022 17:45:00 CEST | Pressemelding

Pressmeddelande 13 maj 2022 Ej för offentliggörande, distribution eller publicering, varken direkt eller indirekt, i eller till Storbritannien, USA, Kanada, Japan, Australien, Hong Kong, Nya Zeeland, Schweiz, Sydafrika eller annan jurisdiktion där offentliggörande, distribution eller publicering skulle vara olaglig eller kräva registrering eller annan åtgärd. Fosielund Holding AB påkallar inlösen av återstående aktier i Hövding Sverige AB (publ) Fosielund Holding AB, org.nr 556140-5167, (”Fosielund Holding”) har idag till styrelsen för Hövding Sverige AB (publ), org.nr 556708-0303, (”Hövding”) påkallat inlösen av återstående aktier i Hövding från de övriga aktieägarna, i enlighet med 22 kap. 1 § aktiebolagslagen. Överenskommelse om inlösen av aktierna har inte kunnat träffas med samtliga övriga aktieägare. Fosielund Holding har därför begärt att tvisten avgörs av skiljemän i enlighet med 22 kap. 6 § aktiebolagslagen. För ytterligare information, vänligen kontakta: Joel Eklund, 040-6701